This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Orchestra Pregnancy Observational Study in Poland

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2014 by Medtronic Poland Spółka z ograniczoną odpowiedzialnością.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Medtronic Poland Spółka z ograniczoną odpowiedzialnością Identifier:
First received: January 28, 2013
Last updated: October 15, 2014
Last verified: October 2014


The aim of this observational study (registry) is to document the use of insulin pump therapy (CSII) and sensor augmented pump therapy (SAP) before, during and after pregnancy in women with Type 1 Diabetes Mellitus benefiting from the Orchestra donation of Paradigm REAL-Time and Paradigm Veo pumps in Poland.


To assess the benefits of CSII and SAP on the maternal glycemic control; To assess the prevalence of pregnancy complications (rates of preterm delivery, infant birth weight, neonatal care admissions) from preconception phase, throughout pregnancy, during delivery and after delivery during lactation phase (up to 6 weeks); To report and assess the potential benefits of SAP or CSII on neonatal outcomes

Type 1 Diabetes Mellitus Pregnancy

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 22 Months
Official Title: A Multi-center Observational Study During Pregnancy for Women With T1DM Treated With the Paradigm Insulin Pumps Donated by the 'Wielka Orkiestra Świątecznej Pomocy' Foundation in Poland

Resource links provided by NLM:

Further study details as provided by Medtronic Poland Spółka z ograniczoną odpowiedzialnością:

Primary Outcome Measures:
  • HbA1c [ Time Frame: 22 months ]
    Maternal glycemic control

Secondary Outcome Measures:
  • Assessment of prevalence of pregnancy complications and neonatal outcomes [ Time Frame: During pregnancy, at delivery and 6 weeks after delivery ]
    Mode of delivery (rates elective and emergency CS, normal), Respiratory distress (1 and 5 minute Apgar scores), Gestational age at delivery, % preterm delivery <37 weeks, Infant birth weight (SD scores and customised birth weight percentile, % large for gestational age (LGA), % small for gestational age (SGA), Neonatal morbidity (treatment for neonatal hypoglycaemia), Neonatal care admission (duration of stay, level of care), Pregnancy related serious adverse events (miscarriage <22 weeks, congenital malformation, stillbirth, neonatal death), Feeding at hospital discharge (breast, bottle, both)

Biospecimen Retention:   None Retained
Whole blood, serum, urine samples as required in routine practice before, during and after pregnancy in women with Type 1 Diabetes Mellitus

Estimated Enrollment: 350
Study Start Date: May 2013
Estimated Study Completion Date: May 2017
Estimated Primary Completion Date: February 2017 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Women with Type 1 Diabetes Mellitus planning pregnancy or being pregnant until the 16th week of pregnacy

Inclusion Criteria:

  • Female diagnosed with Diabetes Mellitus Type 1
  • Subject indicated by HCP to start insulin pump therapy (CSII) or sensor augmented pump therapy (SAP) due to the desired or established pregnancy
  • HCP has prescribed the use of Orchestra donated device to the subject independently of the study
  • Signed Patient Informed Consent (PIC)
  • Subject is 18 to 45 years old, planning immediate pregnancy (within the next 12 months) or being pregnant within the first trimester until the 16th week of amenorrhea
  • Subject has been on MDI for at least 3 months before starting pump therapy

Exclusion Criteria:

  • Subject was enrolled in the registry earlier, and terminated it (for any reason)
  • Participation in any other interventional clinical trial - currently and/or in the last 3 months before the signature of PIC
  • Subject uses an insulin pump that was not donated by the Orchestra foundation
  • Pregnant women with longer than 16 weeks of pregnancy/amenorrhea
  • Subjects who need assisted in vitro fertilization
  • Subjects with Diabetes Mellitus Type 2, Gestational Diabetes, MODY or any other type of diabetes than Type 1
  • Subject under the age of 18
  • Subject legally incompetent
  • Subject cannot read or write
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01779141

Contact: Jacek Sieradzki, Prof
Contact: Katarzyna Cypryk, Prof

Uniwersytecki Szpital Kliniczny w Białymstoku Recruiting
Białystok, Poland, 15-276
Contact: Beata Telejko, MD    +48 602 399 997   
Principal Investigator: Beata Telejko, MD         
NZOZ Specjalistyczny Ośrodek Internistyczno-Diabetologiczny Recruiting
Białystok, Poland, 15-435
Contact: Malgorzata Arciszewska, MD    +48 501 700 730   
Principal Investigator: Malgorzata Arciszewska, MD         
Szpital Wojewódzki w Bielsku Białej Recruiting
Bielsko-Biala, Poland, 43-316
Contact: Iwona Petrulewicz-Salamon, MD    +48 696 484 620   
Principal Investigator: Iwona Petrulewicz-Salamon, MD         
Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszczy Recruiting
Bygdoszcz, Poland, 85-168
Contact: Alina Sokup, MD    +48 509 217 662   
Principal Investigator: Alina Sokup, MD         
Szpital Specjalistyczny w Jaśle Recruiting
Jaslo, Poland, 38-200
Contact: Marta Gorczyca-Pluta, MD    +48 604 637 952   
Principal Investigator: Marta Gorczyca-Pluta, MD         
NZOZ WITAMED Outpatient Diabetes Clinic Recruiting
Kielce, Poland, 25-035
Contact: Grażyna Majcher-Witczak, MD    +48 604 630 953   
Principal Investigator: Grażyna Majcher-Witczak, MD         
Szpital Uniwersytecki w Krakowie Recruiting
Krakow, Poland, 31-501
Contact: Przemysław Witek, MD    +48 609 968 989   
Principal Investigator: Przemysław Witek, MD         
Samodzielny Publiczny Szpital Kliniczny nr 4 Uniwersytetu Medycznego w Lublinie Recruiting
Lublin, Poland, 20-090
Contact: Beata Matyjaszek-Matuszek, MD    +48 604 302 289   
Principal Investigator: Beata Matyjaszek-Matuszek, MD         
Wojewódzki Szpital Specjalistyczny w Olsztynie Recruiting
Olsztyn, Poland, 10-561
Contact: Joanna Rutkowska, MD    +48 605 602 160   
Principal Investigator: Joanna Rutkowska, MD         
PSZOZ Wojewódzkie Centrum Medyczne w Opolu Recruiting
Opole, Poland, 45-418
Contact: Wanda Urbanska, MD    +48 506 267 679   
Principal Investigator: Wanda Urbanska, MD         
Zakład Opieki Zdrowotnej Poznań-Jeżyce Recruiting
Poznan, Poland, 60-834
Contact: Dorota Pisarczyk-Wiza, MD    +48 502 041 751   
Principal Investigator: Dorota Pisarczyk-Wiza, MD         
Clinic of Gynecology and Obstetrics of Marcinkowski Medical University Recruiting
Poznań, Poland, 60-535
Contact: Ewa Wender-Ożegowska, Prof    +48 501 276 060   
Principal Investigator: Ewa Wender-Ożegowska, Prof         
Szpital Wojewódzki nr 2 im. Św. Jadwigi Królowej Recruiting
Rzeszow, Poland, 35-301
Contact: Joanna Kedzierska, MD    +48 502 222 391   
Principal Investigator: Joanna Kedzierska, MD         
Samodzielny Publiczny Wojewódzki Szpital Zespolony w Szczecinie im. Marii Skłodowskiej-Curie Recruiting
Szczecin, Poland, 71-455
Contact: Jaroslaw Ogonowski, MD    +48 608 221 899   
Principal Investigator: Jaroslaw Ogonowski, MD         
Wojewódzki Szpital Zespolony im. L. Rydygiera Recruiting
Torun, Poland, 87-100
Contact: Elzbieta Szymanska, MD    +48 601 644 766   
Principal Investigator: Elzbeita Szymanska, MD         
Szpital Kliniczny im. ks. Anny Mazowieckiej Warszawskiego Uniwersytetu Medycznego Recruiting
Warszawa, Poland, 00-315
Contact: Aneta Malinowska-Polubiec, MD    +48 609 493 935   
Principal Investigator: Aneta Malinowska-Polubiec, MD         
Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie Recruiting
Warszawa, Poland, 02-097
Contact: Malgorzata Puchta, MD    +48 604 498 013   
Principal Investigator: Malgorzata Puchta, MD         
Mazowiecki Szpital Wojewódzki Sp. z o.o. Recruiting
Warszawa, Poland, 03-242
Contact: Izabela Razna, MD    +48 608 652 646   
Principal Investigator: Izabela Raźna, MD         
Wojewódzki Zespół Specjalistycznej Opieki Zdrowotnej Recruiting
Wroclaw, Poland, 50-403
Contact: Dariusz Sowinski, MD    +48 501 424 165   
Principal Investigator: Dariusz Sowinski, MD         
Samodzielny Publiczny Szpital Kliniczny nr 1 im prof. Stanisława Szyszko Recruiting
Zabrze, Poland, 41-800
Contact: Edyta Cichocka, MD    +48 606 943 038   
Principal Investigator: Edyta Cichocka, MD         
Zespół Wojewódzkich Przychodni Specjalistycznych w Katowicach Recruiting
Zabrze, Poland, 41-800
Contact: Marta Wróbel, MD    +48 606 873 060   
Principal Investigator: Marta Wróbel, MD         
NZOZ MED-ART Poradnie Specjalistyczne Sp. z o.o. Recruiting
Zory, Poland, 44-240
Contact: Violetta Szostek-Gawel, MD    +48 501 616 115   
Principal Investigator: Violetta Szostek-Gawel, MD         
Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Łodzi Recruiting
Łódź, Poland, 90-153
Contact: Elektra Szymanska-Garbacz, MD    +48 600 435 885   
Principal Investigator: Elektra Szymanska-Garbacz, MD         
Uniwersytet Medyczny w Łodzi, Klinika Diabetologii Recruiting
Łódź, Poland, 93-338
Contact: Katarzyna Cypryk, Professor    +48 502 150 273   
Principal Investigator: Katarzyna Cypryk, Prof         
Sponsors and Collaborators
Medtronic Poland Spółka z ograniczoną odpowiedzialnością
Study Chair: Jacek Sieradzki, Prof Cracow Medical University
  More Information

Responsible Party: Medtronic Poland Spółka z ograniczoną odpowiedzialnością Identifier: NCT01779141     History of Changes
Other Study ID Numbers: PL01
Study First Received: January 28, 2013
Last Updated: October 15, 2014

Keywords provided by Medtronic Poland Spółka z ograniczoną odpowiedzialnością:
Type 1 Diabetes Mellitus - T1DM
Insulin Pump
Glucose Sensor
Continuous Subcutaneous Insulin Infusion - CSII
Sensor Augmented Pump - SAP
Continuous Glucose Monitoring - CGM

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on September 21, 2017